메뉴 건너뛰기




Volumn 26, Issue 1, 2015, Pages 26-35

Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G2C; IMMUNOGLOBULIN G3; OKT 4; PARVOVIRUS VECTOR; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; UNCLASSIFIED DRUG; ALPHA GLUCOSIDASE; ANTIBODY; CAPSID PROTEIN; CD4 ANTIGEN; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

EID: 84921448380     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2014.115     Document Type: Article
Times cited : (25)

References (61)
  • 1
    • 71649099089 scopus 로고    scopus 로고
    • Crossreactive immunologic material status affects treatment outcomes in Pompe disease infants
    • Kishnani PS, Goldenberg PC, Dearmey SL, et al. Crossreactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 2010;99:26-33.
    • (2010) Mol Genet Metab , vol.99 , pp. 26-33
    • Kishnani, P.S.1    Goldenberg, P.C.2    Dearmey, S.L.3
  • 2
    • 71949101824 scopus 로고    scopus 로고
    • Pompe disease in infants: Improving the prognosis by newborn screening and early treatment
    • Chien YH, Lee NC, Thurberg BL, et al. Pompe disease in infants: improving the prognosis by newborn screening and early treatment. Pediatrics 2009;124:e1116-e1125.
    • (2009) Pediatrics , vol.124 , pp. e1116-e1125
    • Chien, Y.H.1    Lee, N.C.2    Thurberg, B.L.3
  • 3
    • 78649323564 scopus 로고    scopus 로고
    • High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa
    • De Vries JM, Van Der Beek NA, Kroos MA, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 2010;101:338-345.
    • (2010) Mol Genet Metab , vol.101 , pp. 338-345
    • De Vries, J.M.1    Van Der-Beek, N.A.2    Kroos, M.A.3
  • 4
    • 84862827574 scopus 로고    scopus 로고
    • Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: Need for agents to target antibodysecreting plasma cells
    • Banugaria SG, Patel TT, Mackey J, et al. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibodysecreting plasma cells. Mol Genet Metab 2012;105:677-680.
    • (2012) Mol Genet Metab , vol.105 , pp. 677-680
    • Banugaria, S.G.1    Patel, T.T.2    MacKey, J.3
  • 5
    • 0035746540 scopus 로고    scopus 로고
    • Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial
    • Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3:132-138.
    • (2001) Genet Med , vol.3 , pp. 132-138
    • Amalfitano, A.1    Bengur, A.R.2    Morse, R.P.3
  • 6
    • 84881145296 scopus 로고    scopus 로고
    • Immune modulation therapy in a CRIM-positive and IgG antibodypositive infant with Pompe disease treated with alglucosidase alfa: A case report
    • Markic J, Polic B, Kuzmanic-Samija R, et al. Immune modulation therapy in a CRIM-positive and IgG antibodypositive infant with Pompe disease treated with alglucosidase alfa: a case report. JIMD Rep 2012;2:11-15.
    • (2012) JIMD Rep , vol.2 , pp. 11-15
    • Markic, J.1    Polic, B.2    Kuzmanic-Samija, R.3
  • 7
    • 84897024760 scopus 로고    scopus 로고
    • Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: A 3-year follow-up study
    • Markic J, Polic B, Stricevic L, et al. Effects of immune modulation therapy in the first Croatian infant diagnosed with Pompe disease: a 3-year follow-up study. Wien Klin Wochenschr 2014;126:133-137.
    • (2014) Wien Klin Wochenschr , vol.126 , pp. 133-137
    • Markic, J.1    Polic, B.2    Stricevic, L.3
  • 8
    • 84855542158 scopus 로고    scopus 로고
    • Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease
    • Messinger YH, Mendelsohn NJ, Rhead W, et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 2012;14:135-142.
    • (2012) Genet Med , vol.14 , pp. 135-142
    • Messinger, Y.H.1    Mendelsohn, N.J.2    Rhead, W.3
  • 9
    • 84879340927 scopus 로고    scopus 로고
    • Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: A step towards improving the efficacy of ERT
    • Banugaria SG, Prater SN, Patel TT, et al. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile Pompe disease: a step towards improving the efficacy of ERT. PLoS One 2013;8:e67052.
    • (2013) PLoS One , vol.8 , pp. e67052
    • Banugaria, S.G.1    Prater, S.N.2    Patel, T.T.3
  • 10
    • 34548613865 scopus 로고    scopus 로고
    • Role of autophagy in the pathogenesis of Pompe disease
    • Raben N, Roberts A, and Plotz PH. Role of autophagy in the pathogenesis of Pompe disease. Acta Myol 2007;26:45-48.
    • (2007) Acta Myol , vol.26 , pp. 45-48
    • Raben, N.1    Roberts, A.2    Plotz, P.H.3
  • 11
    • 78649288882 scopus 로고    scopus 로고
    • Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder-murine Pompe disease
    • Raben N, Schreiner C, Baum R, et al. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder-murine Pompe disease. Autophagy 2010;6:1078-1089.
    • (2010) Autophagy , vol.6 , pp. 1078-1089
    • Raben, N.1    Schreiner, C.2    Baum, R.3
  • 12
    • 84877601173 scopus 로고    scopus 로고
    • Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
    • Spampanato C, Feeney E, Li L, et al. Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease. EMBO Mol Med 2013;5:691-706.
    • (2013) EMBO Mol Med , vol.5 , pp. 691-706
    • Spampanato, C.1    Feeney, E.2    Li, L.3
  • 13
    • 0142089744 scopus 로고    scopus 로고
    • Enzyme replacement therapy in the mouse model of Pompe disease
    • Raben N, Danon M, Gilbert AL, et al. Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 2003;80:159-169.
    • (2003) Mol Genet Metab , vol.80 , pp. 159-169
    • Raben, N.1    Danon, M.2    Gilbert, A.L.3
  • 14
    • 27744533046 scopus 로고    scopus 로고
    • Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II
    • Franco LM, Sun B, Yang X, et al. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. Mol Ther 2005;12:876-884.
    • (2005) Mol Ther , vol.12 , pp. 876-884
    • Franco, L.M.1    Sun, B.2    Yang, X.3
  • 15
    • 76349113832 scopus 로고    scopus 로고
    • Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine Pompe disease
    • Sun B, Kulis MD, Young SP, et al. Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine Pompe disease. Mol Ther 2010;18:353-360.
    • (2010) Mol Ther , vol.18 , pp. 353-360
    • Sun, B.1    Kulis, M.D.2    Young, S.P.3
  • 16
    • 84861682930 scopus 로고    scopus 로고
    • Immunodominant liverspecific expression suppresses transgene-directed immune responses in murine Pompe disease
    • Zhang P, Sun B, Osada T, et al. Immunodominant liverspecific expression suppresses transgene-directed immune responses in murine Pompe disease. Hum Gene Ther 2012; 23:460-472.
    • (2012) Hum Gene Ther , vol.23 , pp. 460-472
    • Zhang, P.1    Sun, B.2    Osada, T.3
  • 17
    • 34547498762 scopus 로고    scopus 로고
    • + T cells in tolerance to the transgene product following hepatic in vivo gene transfer
    • + T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 2007;110:1132-1140.
    • (2007) Blood , vol.110 , pp. 1132-1140
    • Cao, O.1    Dobrzynski, E.2    Wang, L.3
  • 18
    • 80053377114 scopus 로고    scopus 로고
    • Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease
    • Banati M, Hosszu Z, Trauninger A, et al. Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease. Muscle Nerve 2011;44:720-726.
    • (2011) Muscle Nerve , vol.44 , pp. 720-726
    • Banati, M.1    Hosszu, Z.2    Trauninger, A.3
  • 19
    • 0022642908 scopus 로고
    • Induction of tolerance by monoclonal antibody therapy
    • Benjamin RJ, and Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature 1986;320:449-451.
    • (1986) Nature , vol.320 , pp. 449-451
    • Benjamin, R.J.1    Waldmann, H.2
  • 20
    • 0024549385 scopus 로고
    • Induction of classical transplantation tolerance in the adult
    • Qin SX, Cobbold S, Benjamin R, et al. Induction of classical transplantation tolerance in the adult. J Exp Med 1989;169:779-794.
    • (1989) J Exp Med , vol.169 , pp. 779-794
    • Qin, S.X.1    Cobbold, S.2    Benjamin, R.3
  • 21
    • 0027272545 scopus 로고
    • Prevention of diabetes but not insulitis in NOD mice injected with antibody to CD4
    • Hayward AR, Shriber M, Cooke A, et al. Prevention of diabetes but not insulitis in NOD mice injected with antibody to CD4. J Autoimmun 1993;6:301-310.
    • (1993) J Autoimmun , vol.6 , pp. 301-310
    • Hayward, A.R.1    Shriber, M.2    Cooke, A.3
  • 22
    • 7244242322 scopus 로고    scopus 로고
    • Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen induced arthritis: Influence on macrophage activation
    • Nissler K, Pohlers D, Huckel M, et al. Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen induced arthritis: influence on macrophage activation. Ann Rheum Dis 2004;63:1470-1477.
    • (2004) Ann Rheum Dis , vol.63 , pp. 1470-1477
    • Nissler, K.1    Pohlers, D.2    Huckel, M.3
  • 23
    • 14844352743 scopus 로고    scopus 로고
    • + regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: Antigen-specific reactivation in vivo is critical for bystander regulation
    • + regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. Blood 2005;105:4871-4877.
    • (2005) Blood , vol.105 , pp. 4871-4877
    • Karim, M.1    Feng, G.2    Wood, K.J.3
  • 24
    • 84916603606 scopus 로고    scopus 로고
    • Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease
    • Sun B, Banugaria SG, Prater SN, et al. Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease. Mol Genet Metab 2014;1:446-450.
    • (2014) Mol Genet Metab , vol.1 , pp. 446-450
    • Sun, B.1    Banugaria, S.G.2    Prater, S.N.3
  • 25
    • 84855445997 scopus 로고    scopus 로고
    • Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine
    • McIntosh JH, Cochrane M, Cobbold S, et al. Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine. Gene Ther 2011;19:78-85.
    • (2011) Gene Ther , vol.19 , pp. 78-85
    • McIntosh, J.H.1    Cochrane, M.2    Cobbold, S.3
  • 26
    • 0346777307 scopus 로고    scopus 로고
    • Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo
    • McCarty DM, Fu H, Monahan PE, et al. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003;10:2112-2118.
    • (2003) Gene Ther , vol.10 , pp. 2112-2118
    • McCarty, D.M.1    Fu, H.2    Monahan, P.E.3
  • 27
    • 10944239670 scopus 로고    scopus 로고
    • Efficacy of an adenoassociated virus 8-pseudotyped vector in glycogen storage disease type II
    • Sun B, Zhang H, Franco LM, et al. Efficacy of an adenoassociated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Ther 2005;11:57-65.
    • (2005) Mol Ther , vol.11 , pp. 57-65
    • Sun, B.1    Zhang, H.2    Franco, L.M.3
  • 28
    • 0037015049 scopus 로고    scopus 로고
    • Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
    • Gao GP, Alvira MR, Wang L, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 2002;99:11854-11859.
    • (2002) Proc Natl Acad Sci U S A , vol.99 , pp. 11854-11859
    • Gao, G.P.1    Alvira, M.R.2    Wang, L.3
  • 29
    • 0033529902 scopus 로고    scopus 로고
    • Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase
    • Amalfitano A, Mcvie-Wylie AJ, Hu H, et al. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci U S A 1999;96:8861-8866.
    • (1999) Proc Natl Acad Sci U S A , vol.96 , pp. 8861-8866
    • Amalfitano, A.1    McVie-Wylie, A.J.2    Hu, H.3
  • 30
    • 0036226791 scopus 로고    scopus 로고
    • Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction
    • Ding E, Hu H, Hodges BL, et al. Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol Ther 2002;5:436-446.
    • (2002) Mol Ther , vol.5 , pp. 436-446
    • Ding, E.1    Hu, H.2    Hodges, B.L.3
  • 31
    • 0028027043 scopus 로고
    • Mechanisms in CD4 antibody-mediated transplantation tolerance: Kinetics of induction, antigen dependency and role of regulatory T cells
    • Scully R, Qin S, Cobbold S, et al. Mechanisms in CD4 antibody-mediated transplantation tolerance: kinetics of induction, antigen dependency and role of regulatory T cells. Eur J Immunol 1994;24:2383-2392.
    • (1994) Eur J Immunol , vol.24 , pp. 2383-2392
    • Scully, R.1    Qin, S.2    Cobbold, S.3
  • 32
    • 4644328028 scopus 로고    scopus 로고
    • Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody
    • Winsor-Hines D, Merrill C, O'Mahony M, et al. Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody. J Immunol 2004;173: 4715-4723.
    • (2004) J Immunol , vol.173 , pp. 4715-4723
    • Winsor-Hines, D.1    Merrill, C.2    O'Mahony, M.3
  • 33
    • 78649508777 scopus 로고    scopus 로고
    • Antibody formation and mannose- 6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease
    • Sun B, Li S, Bird A, et al. Antibody formation and mannose- 6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease. J Gene Med 2010;12:881-891.
    • (2010) J Gene Med , vol.12 , pp. 881-891
    • Sun, B.1    Li, S.2    Bird, A.3
  • 34
    • 84864006285 scopus 로고    scopus 로고
    • The pharmacological chaperone AT2220 increases recombinant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease
    • Khanna R, Flanagan JJ, Feng J, et al. The pharmacological chaperone AT2220 increases recombinant human acid alpha-glucosidase uptake and glycogen reduction in a mouse model of Pompe disease. PLoS One 2012;7:e40776.
    • (2012) PLoS One , vol.7 , pp. e40776
    • Khanna, R.1    Flanagan, J.J.2    Feng, J.3
  • 35
    • 19444362297 scopus 로고    scopus 로고
    • Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter
    • Sun B, Zhang H, Franco LM, et al. Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. Mol Ther 2005;11: 889-898.
    • (2005) Mol Ther , vol.11 , pp. 889-898
    • Sun, B.1    Zhang, H.2    Franco, L.M.3
  • 36
    • 0030795691 scopus 로고    scopus 로고
    • Transduction by adeno-associated virus vectors in the rabbit airway: Efficiency, persistence, and readministration
    • Halbert CL, Standaert TA, Aitken ML, et al. Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration. J Virol 1997;71: 5932-5941.
    • (1997) J Virol , vol.71 , pp. 5932-5941
    • Halbert, C.L.1    Standaert, T.A.2    Aitken, M.L.3
  • 37
    • 17044394814 scopus 로고    scopus 로고
    • Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV28-mediated liver-directed gene therapy
    • Wang LL, Calcedo R, Nichols TC, et al. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV28-mediated liver-directed gene therapy. Blood 2005;105:3079-3086.
    • (2005) Blood , vol.105 , pp. 3079-3086
    • Wang, L.L.1    Calcedo, R.2    Nichols, T.C.3
  • 38
    • 84860155178 scopus 로고    scopus 로고
    • Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia
    • Demaster A, Luo X, Curtis S, et al. Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia. Hum Gene Ther 2012;23:407-418.
    • (2012) Hum Gene Ther , vol.23 , pp. 407-418
    • Demaster, A.1    Luo, X.2    Curtis, S.3
  • 39
    • 0036099319 scopus 로고    scopus 로고
    • Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors
    • Fraites TJ, Schleissing MR, Shanely RA, et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 2002;5:571-578.
    • (2002) Mol Ther , vol.5 , pp. 571-578
    • Fraites, T.J.1    Schleissing, M.R.2    Shanely, R.A.3
  • 40
    • 33847206112 scopus 로고    scopus 로고
    • Physiological correction of Pompe disease by systemic delivery of adenoassociated virus serotype 1 vectors
    • Mah C, Pacak CA, Cresawn KO, et al. Physiological correction of Pompe disease by systemic delivery of adenoassociated virus serotype 1 vectors. Mol Ther 2007;15: 501-507.
    • (2007) Mol Ther , vol.15 , pp. 501-507
    • Mah, C.1    Pacak, C.A.2    Cresawn, K.O.3
  • 41
    • 13844264229 scopus 로고    scopus 로고
    • Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alphaglucosidase in a model of glycogen storage disease type II
    • Cresawn KO, Fraites TJ, Wasserfall C, et al. Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alphaglucosidase in a model of glycogen storage disease type II. Hum Gene Ther 2005;16:68-80.
    • (2005) Hum Gene Ther , vol.16 , pp. 68-80
    • Cresawn, K.O.1    Fraites, T.J.2    Wasserfall, C.3
  • 42
    • 35348926853 scopus 로고    scopus 로고
    • Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance
    • Sun B, Bird A, Young SP, et al. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet 2007;81: 1042-1049.
    • (2007) Am J Hum Genet , vol.81 , pp. 1042-1049
    • Sun, B.1    Bird, A.2    Young, S.P.3
  • 43
    • 80051799963 scopus 로고    scopus 로고
    • The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease
    • Banugaria SG, Prater SN, Ng YK, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 2011;13:729-736.
    • (2011) Genet Med , vol.13 , pp. 729-736
    • Banugaria, S.G.1    Prater, S.N.2    Ng, Y.K.3
  • 44
    • 80455174006 scopus 로고    scopus 로고
    • Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector
    • Luo X, Hall G, Li S, et al. Hepatorenal correction in murine glycogen storage disease type I with a double-stranded adeno-associated virus vector. Mol Ther 2011;19:1961-1970.
    • (2011) Mol Ther , vol.19 , pp. 1961-1970
    • Luo, X.1    Hall, G.2    Li, S.3
  • 45
    • 84908242541 scopus 로고    scopus 로고
    • Deficiency in MyD88 signaling results in decreased antibody responses to an adenoassociated virus vector in murine Pompe disease
    • Zhang P, Luo X, Bird A, et al. Deficiency in MyD88 signaling results in decreased antibody responses to an adenoassociated virus vector in murine Pompe disease. Biores Open Access 2012;1:109-114.
    • (2012) Biores Open Access , vol.1 , pp. 109-114
    • Zhang, P.1    Luo, X.2    Bird, A.3
  • 46
    • 46249131028 scopus 로고    scopus 로고
    • Ability of adenoassociated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice
    • Ziegler RJ, Bercury SD, Fidler J, et al. Ability of adenoassociated virus serotype 8-mediated hepatic expression of acid alpha-glucosidase to correct the biochemical and motor function deficits of presymptomatic and symptomatic Pompe mice. Hum Gene Ther 2008;19:609-621.
    • (2008) Hum Gene Ther , vol.19 , pp. 609-621
    • Ziegler, R.J.1    Bercury, S.D.2    Fidler, J.3
  • 47
    • 84921528269 scopus 로고    scopus 로고
    • Assessment of toxicity and biodistribution of recombinant AAV2/8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease
    • Wang G, Young S, Bali D, et al. Assessment of toxicity and biodistribution of recombinant AAV2/8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease. Mol Ther Methods Clin Dev 2014;1:14018.
    • (2014) Mol Ther Methods Clin Dev , vol.1 , pp. 14018
    • Wang, G.1    Young, S.2    Bali, D.3
  • 48
    • 48349114962 scopus 로고    scopus 로고
    • Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy
    • Sun B, Young SP, Li P, et al. Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy. Mol Ther 2008;16:1366-1371.
    • (2008) Mol Ther , vol.16 , pp. 1366-1371
    • Sun, B.1    Young, S.P.2    Li, P.3
  • 49
    • 34547514608 scopus 로고    scopus 로고
    • Muscle as a target for supplementary factor IX gene transfer
    • Hoffman BE, Dobrzynski E, Wang L, et al. Muscle as a target for supplementary factor IX gene transfer. Hum Gene Ther 2007;18:603-613.
    • (2007) Hum Gene Ther , vol.18 , pp. 603-613
    • Hoffman, B.E.1    Dobrzynski, E.2    Wang, L.3
  • 50
    • 78650608742 scopus 로고    scopus 로고
    • FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo
    • Nimmerjahn F, Lux A, Albert H, et al. FcgammaRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc Natl Acad Sci U S A 2010;107:19396-19401.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 19396-19401
    • Nimmerjahn, F.1    Lux, A.2    Albert, H.3
  • 51
    • 7244236586 scopus 로고    scopus 로고
    • Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model
    • Xu F, Ding E, Liao SX, et al. Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model. Gene Ther 2004; 11:1590-1598.
    • (2004) Gene Ther , vol.11 , pp. 1590-1598
    • Xu, F.1    Ding, E.2    Liao, S.X.3
  • 52
    • 33947196295 scopus 로고    scopus 로고
    • + T cells are unable to eliminate AAVtransduced hepatocytes
    • + T cells are unable to eliminate AAVtransduced hepatocytes. Mol Ther 2007;15:792-800.
    • (2007) Mol Ther , vol.15 , pp. 792-800
    • Li, H.1    Murphy, S.L.2    Giles-Davis, W.3
  • 53
    • 77954976233 scopus 로고    scopus 로고
    • Prevalence of serum IgG and neutralizing factors against adeno-associated virus types 1, 2, 5, 6, 8 and 9 in the healthy population: Implications for gene therapy using AAV sectors
    • Boutin S, Monteilhet V, Veron P, et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus types 1, 2, 5, 6, 8 and 9 in the healthy population: implications for gene therapy using AAV sectors. Hum Gene Ther 2010;21:704-771.
    • (2010) Hum Gene Ther , vol.21 , pp. 704-771
    • Boutin, S.1    Monteilhet, V.2    Veron, P.3
  • 54
    • 21244487991 scopus 로고    scopus 로고
    • Major role of local immune responses in antibody formation to factor IX in AAV gene transfer
    • Wang L, Cao O, Swalm B, et al. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther 2005;12:1453-1464.
    • (2005) Gene Ther , vol.12 , pp. 1453-1464
    • Wang, L.1    Cao, O.2    Swalm, B.3
  • 55
    • 84863480768 scopus 로고    scopus 로고
    • Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B
    • Mingozzi F, Chen Y, Murphy SL, et al. Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. Mol Ther 2012;20:1410-1416.
    • (2012) Mol Ther , vol.20 , pp. 1410-1416
    • Mingozzi, F.1    Chen, Y.2    Murphy, S.L.3
  • 56
    • 84878746264 scopus 로고    scopus 로고
    • Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy
    • Louis Jeune V, Joergensen JA, Hajjar RJ, et al. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods 2013;24:59-67.
    • (2013) Hum Gene Ther Methods , vol.24 , pp. 59-67
    • Louis Jeune, V.1    Joergensen, J.A.2    Hajjar, R.J.3
  • 57
    • 33745606715 scopus 로고    scopus 로고
    • Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs
    • Jiang H, Lillicrap D, Patarroyo-White S, et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 2006;108:107-115.
    • (2006) Blood , vol.108 , pp. 107-115
    • Jiang, H.1    Lillicrap, D.2    Patarroyo-White, S.3
  • 58
    • 33344466244 scopus 로고    scopus 로고
    • Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice
    • Scallan CD, Jiang H, Liu T, et al. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 2006;107:1810-1817.
    • (2006) Blood , vol.107 , pp. 1810-1817
    • Scallan, C.D.1    Jiang, H.2    Liu, T.3
  • 59
    • 80052496589 scopus 로고    scopus 로고
    • Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors
    • Wang L, Calcedo R, Bell P, et al. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther 2011;22: 1389-1401.
    • (2011) Hum Gene Ther , vol.22 , pp. 1389-1401
    • Wang, L.1    Calcedo, R.2    Bell, P.3
  • 60
    • 77957943865 scopus 로고    scopus 로고
    • Adeno-associated virus-mediated correction of a canine model of glycogen storage disease type Ia
    • Weinstein DA, Correia CE, Conlon T, et al. Adeno-associated virus-mediated correction of a canine model of glycogen storage disease type Ia. Hum Gene Ther 2010;21:903-910.
    • (2010) Hum Gene Ther , vol.21 , pp. 903-910
    • Weinstein, D.A.1    Correia, C.E.2    Conlon, T.3
  • 61
    • 0000995321 scopus 로고    scopus 로고
    • Glycogen storage disease type II: Acid α-glucosidase (acid maltase) deficiency
    • CR Scriver, AL Beaudet, WS Sly, and D Valle, eds. (McGraw-Hill, New York, NY)
    • Hirschhorn R, and Reuser AJJ. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. In: The Metabolic and Molecular Basis for Inherited Disease. CR Scriver, AL Beaudet, WS Sly, and D Valle, eds. (McGraw-Hill, New York, NY) 2001; pp. 3389-3419.
    • (2001) The Metabolic and Molecular Basis for Inherited Disease , pp. 3389-3419
    • Hirschhorn, R.1    Reuser, A.J.J.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.